Industrial property

Extensive patent portfolio

Our commitment to developing innovative therapies has led us to build a broad, globally extended patent portfolio that continues to grow with new advances and innovations resulting from our ongoing research and development work.

International coverage

With extension in more than 50 territories worldwide, we currently have a portfolio of more than 270 granted patents and pending applications, covering oligonucleotides and RNAi products that regulate the expression of proteins involved in different diseases, and their use in therapy, mainly for ophthalmological indications.